Bristol Myers Squibb (BMS) is generating investor buzz with its late-stage pipeline despite a modest Q1 2026 financial performance. The company is strategically positioning new assets to drive growth into the 2030s as legacy products face loss of exclusivity.
1. Steady Financial Performance
Q1 2026 total revenue reached $11.5 billion, a slight 1% year-over-year increase, beating consensus estimates.
-
Camzyos: A standout performer in the growth portfolio, posting a 97% revenue surge to $314 million.
-
Eliquis: Remained the top earner with $4.1 billion in global sales (up 16%). However, its looming 2027 patent expiry remains a central focus for the company’s long-term strategy.
2. Milvexian: The Heir to the Eliquis Franchise
BMS is heavily betting on Milvexian, a next-generation FXIa inhibitor anticoagulant.
-
Market Potential: Executives tout it as a drug with “true blockbuster potential,” contingent on proving a superior safety profile regarding bleeding and efficacy compared to current standards.
-
Key Milestones: Pivotal Phase III readouts for atrial fibrillation and secondary stroke prevention are expected later this year.
3. Cobenfy: Expansion into Alzheimer’s Care
While market uptake for Cobenfy in schizophrenia has been gradual, BMS is eyeing significant expansion:
-
Alzheimer’s Psychosis: Data from the pivotal ADEPT clinical program is expected in late 2026.
-
Long-term Forecast: With potential expansions into bipolar-I and Alzheimer’s-related agitation, analysts project Cobenfy sales could reach $2.2 billion by 2030.
4. 2026 Outlook
BMS reaffirmed its full-year guidance with anticipated revenues between $46 billion and $47.5 billion. The company’s trajectory heavily relies on the success of its late-stage readouts to navigate the impending transition of its core portfolio.